Ryanodine Receptor 2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ryanodine receptor 2 (RyR2) is the principal calcium release channel of the cardiac sarcoplasmic reticulum (SR), where it is essential for excitation-contraction coupling in heart muscle cells. Cardiac RyR2 is activated by calcium influx through L-type calcium channels (Cav1.2) via calcium-induced calcium release (CICR). RyR2 is a homotetramer forming one of the largest known ion channel complexes, and its function is modulated by numerous regulatory proteins including FKBP12.6, calstabin, PKA, and calmodulin. In the brain, RyR2 is expressed in various neuronal populations including hippocampal neurons and cerebellar granule cells, where it contributes to synaptic plasticity and calcium signaling. Mutations in the RYR2 gene cause catecholaminergic polymorphic ventricular tachycardia (CPVT), a potentially fatal arrhythmia disorder. RyR2 dysfunction has also been implicated in heart failure and neurodegenerative diseases.
| Ryanodine Receptor 2 Protein | |
|---|---|
| Protein Name | Ryanodine Receptor 2 Protein |
| Gene | RYR2 |
| UniProt ID | Q92736 |
| PDB IDs | 5GOA, 6JHL, 6BLL |
| Molecular Weight | 565 kDa |
| Subcellular Location | Sarcoplasmic reticulum membrane (cardiac) |
| Protein Family | Ryanodine receptor family |
Ryanodine Receptor 2 Protein is a Ryanodine receptor family. This protein contains characteristic transmembrane domains and regulatory domains that control channel activity and calcium release.
RYR2 is the cardiac ryanodine receptor, essential for calcium-induced calcium release in heart muscle. During each cardiac cycle, calcium influx through L-type calcium channels triggers RYR2-mediated calcium release from the sarcoplasmic reticulum, causing contraction. RYR2 is regulated by PKA phosphorylation (beta-adrenergic signaling), calstabin (FKBP12.6), and calcium. Abnormal RYR2 function causes ventricular arrhythmias and heart failure.
RYR2 mutations cause catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventricular cardiomyopathy (ARVC). RYR2 dysfunction is implicated in AD cardiac pathology and heart failure.
Beta-blockers and flecainide are used for CPVT. RYR2 stabilizers (e.g., carvedilol analogs) are under investigation. Gene therapy approaches are being developed.
The study of Ryanodine Receptor 2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.